Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Hot Flashes
Interventions
DRUG

Gabapentin Extended Release

Gabapentin ER 1800mg daily

DRUG

Placebo

Sugar pill

Trial Locations (66)

Unknown

Birmingham

Mobile

Phoenix

Scottsdale

Tucson

Little Rock

Berkeley

Roseville

San Diego

Denver

Danbury

Milford

Brooksville

Clearwater

DeLand

Gainesville

Naples

New Port Richey

North Miami

Orlando

Decatur

Idaho Falls

Indianapolis

South Bend

Overland Park

Louisville

New Orleans

Paw Paw

Brooklyn Center

Las Vegas

Reno

Moorestown

Plainsboro

Albuquerque

Charlotte

New Bern

Raleigh

Winston-Salem

Bismarck

Fargo

Akron

Cincinnati

Cleveland

Columbus

Kettering

Oklahoma City

Eugene

Philadelphia

Pittsburgh

West Reading

Wexford

Warwick

Anderson

Columbia

Goose Creek

Greer

Rapid City

Chattanooga

Nashville

Dallas

Lake Jackson

San Antonio

Salt Lake City

Charlottesville

Richmond

Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Depomed

INDUSTRY

NCT01080300 - Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women | Biotech Hunter | Biotech Hunter